Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences.

Expert opinion on drug discovery - 1 Nov 2012

Thomas Xavier

Abstract excerpt

INTRODUCTION: DNA methylation is an epigenetic change mediated by DNA methyltranferases (DNMTs), which are promising epigenetic targets for the treatment of acute myeloid leukemia (AML). This is evidenced by the two DNMT inhibitors (azacitidine and decitabine) approved by the Food and Drug Administration of the United States for the treatment of high-risk myelodysplastic syndromes and the first clinical data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to DNA Modification Methylases
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenomics

Share to SCT gene

Share to Leukemia, Myeloid, Acute

Share to Mutation

Source

Identifiers

PMID: 22950862
DOI: 10.1517/17460441.2012.722618

Genes

SCT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences.PMID 22950862Read ↗

DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studiesSemantic proximity Read ↗

DNA Methyltransferase Inhibitors and their Therapeutic PotentialSemantic proximity Read ↗

DNA methyltransferase-1 in acute myeloid leukaemia: beyond the maintenance of DNA methylationSemantic proximity Read ↗

DNA methyltransferases in hematologic malignancies.Semantic proximity Read ↗

Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.Semantic proximity Read ↗

Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid LeukaemiaSemantic proximity Read ↗

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic ToolSemantic proximity Read ↗

Clinical Results of Hypomethylating Agents in AML TreatmentSemantic proximity Read ↗

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersSemantic proximity Read ↗

Significance of targeting DNMT3A mutations in AML.Semantic proximity Read ↗

DNA Methylation–Targeted DrugsSemantic proximity Read ↗

Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.